Comparative Pharmacology
Head-to-head clinical analysis: GASTROGRAFIN versus OMNIPAQUE 9.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GASTROGRAFIN versus OMNIPAQUE 9.
GASTROGRAFIN vs OMNIPAQUE 9
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gastrografin is a water-soluble iodinated contrast agent that increases the radiodensity of the gastrointestinal tract, allowing visualization on X-ray. It acts by absorbing X-rays due to its high iodine content.
Iodinated nonionic contrast agent that attenuates X-rays, enhancing vascular and tissue contrast. Its iodine content (350 mg/mL) provides radiopacity, while low osmolality reduces adverse hemodynamic effects.
Oral or rectal: 50-100 mL of a 1:1 dilution with water (or full strength as needed) for CT or fluoroscopic studies. Typically single dose.
Omnipaque 9 (iohexol 9 mg I/mL) is administered intravenously. For CT enhancement, typical adult dose is 50-100 mL (450-900 mg I) by slow IV injection.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (for absorbed diatrizoate); prolongation in renal impairment (up to 20 hours in anuria).
Terminal elimination half-life: 1–2 hours in patients with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Renal: 80-90% (glomerular filtration, unchanged); Biliary/Fecal: <5% (minor biliary excretion of absorbed fraction).
Renal: >95% unchanged via glomerular filtration; fecal: <1%.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent